Larry Smarr, PhD, Founding Director of of CALIT2, ushers in a new era of medicine with 3D visualization software as well as 3D printing. This technology will revolutionize…
NEW YORK (Reuters Health) – Inflammatory bowel disease (IBD) activity is an independent risk factor for the development of venous thromboembolic events (VTEs). That’s one of the findings…
NEW YORK (Reuters Health) – Complete visualization of the entire small intestine is achieved more easily with double-balloon endoscopy than with single-balloon endoscopy, according to a report from…
NEW YORK (Reuters Health) – After surgically induced remission of Crohn’s disease, treatment with mesalamine reduces the risk of relapse somewhat; sulfasalazine, however, has no apparent benefit, according…
NEW YORK (Reuters Health) – Patients with relapsing mild-to-moderate ulcerative colitis (UC) on immunosuppressive therapy may benefit from the addition of a high-potency probiotic mixture (VSL#3; VSL Pharmaceuticals…
NEW YORK (Reuters Health) – The “dramatic benefits” of probiotic supplements for reducing death and necrotizing enterocolitis (NEC) in very low birth weight (VLBW) preterm neonates have been…
NEW YORK (Reuters Health) – In adults with moderate-to-severe active Crohn’s disease, treatment with infliximab plus azathioprine, or infliximab alone, led to significantly higher rates of corticosteroid-free clinical…
NEW YORK (Reuters Health) – Prophylactic antibiotics may improve survival of burn patients, a meta-analysis suggests, although the authors acknowledge that the quality of the supporting data is…
NEW YORK (Reuters Health) – Long-term treatment with clofazimine or nitroimidazoles may help control Crohn’s disease, according to the authors of a systematic review and meta-analysis. Several bacteria…
NEW YORK (Reuters Health) – Patients taking azathioprine or 6-mercaptopurine for inflammatory bowel disease (IBD) have more than a five-times higher risk of developing a lymphoproliferative disorder compared…
